Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
July 7, 2023
PHILADELPHIA, June 27, 2023 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the European Commission (EC) has granted approval for Opfolda® (miglustat) 65mg capsules, an enzyme stabilizer of cipaglucosidase alfa, a long-term enzyme replacement therapy for adults with late-onset Pompe disease. Pombiliti® (cipaglucosidase alfa) was previously approved by the EC in March 2023. Pompe disease is an inherited lysosomal disorder caused by deficiency of the enzyme acid α-glucosidase (GAA). Amicus plans to immediately launch Pombiliti + Opfolda in Germany and is commencing reimbursement processes with healthcare authorities in other European countries.
Click here for more information
OTHER NEWS
Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Phase 1/2 Study
Excerpt . . . . CRANBURY, N.J., May 15, 2017 —Amicus Therapeutics today announced positive functional data from initial patients in a global Phase 1/2 study (ATB200-02) to investigate ATB200/AT2221 in patients with Pompe disease. Patients who completed six months of...
2017 PCMA of Texas Pull for Pompe!
The AMDA is excited to announce that the 2017 PCMA of Texas Pull for Pompe will take place on Saturday, March 25th at the National Shooting Complex in San Antonio, Texas! This is the 7th Annual Pull for Pompe hosted by the PCMA of Texas. The Pull for Pompe clay...
2016 Helen Walker Research Grant Awarded
The seventh annual AMDA Research Grant (the 2016 Helen Walker Research Grant) was awarded to Dr. Frédéric Lofaso with the Hôpital Raymond Poincaré in France for his Project: “Acid Maltase Deficiency Myopathy Follow-Up.” The aim of this project is to improve the...
Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy
Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease Cambridge, Mass. – November 4, 2016 - Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the first patient has been...
2016 Helen Walker Research Grant For Pompe Disease Now Accepting Applications
The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe Disease research. This grant opportunity was made possible by the 2016 Pull for Pompe, a private fundraiser held by the Precast Manufacturer’s Association of Texas...
The History of PCMA of Texas’s Pull for Pompe! Thank you!
BioMarin Update for the Pompe Community Regarding BMN 701
The IPA Board was provided with the following statement regarding Biomarin’s BMN-701 study. If you have any questions or concerns please contact the IPA at . If and when more information is available the IPA will inform you as soon as possible. BioMarin greatly...
IPA Statement on Biomarin’s June 9th announcement it will seek to out-license BMN-701
Please visit the IPA website to view the statement: http://worldpompe.org/index.php/news/590-ipa-statement-on-biomarin-s-june-9th-announcement-it-will-seek-to-out-license-bmn-701
UPDATE: 2015 AMDA International Pompe Patient and Scientific Conference – Summary Report
UPDATE: DVD recordings of the Conference are available for purchase through the AMDA. The recordings include all presentations and Question and Answer Sessions from the Conference, and can be purchased for $60 (shipping within the US included). To order your DVD set,...
Celebrating the Pompe Community
In recognition of the third annual International Pompe Day, and the 10 Year Anniversary of the approval of Myozyme, Genzyme developed a video highlighting how far the Pompe community has come in the last 10 years, and our hopes for the future. Please find the video...